Back to Search
Start Over
Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects
- Source :
- American Journal of Physiology-Gastrointestinal and Liver Physiology. 296:G482-G489
- Publication Year :
- 2009
- Publisher :
- American Physiological Society, 2009.
-
Abstract
- Enc, FY, Ones,T, Akin HL, Dede F, Turoglu HT, Ulfer G, Bekiroglu N, Haklar G, Rehfeld JF, Holst JJ, Ulusoy NB, Imeryuz N. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. Am J Physiol Gastrointest Liver Physiol 296: G482-G489, 2009. First published December 24, 2008; doi:10.1152/ajpgi.90209.2008.-Orlistat, an inhibitor of digestive lipases, is widely used for the treatment of obesity. Previous reports on the effect of orally ingested orlistat together with a meal on gastric emptying and secretion of gut peptides that modulate postprandial responses are controversial. We investigated the effect of ingested orlistat on gastric emptying and plasma responses of gut peptides in response to a solid mixed meal with a moderate energy load. In healthy subjects, gastric emptying was determined using scintigraphy and studies were performed without and with 120 mg of orlistat in pellet form in random order. Orlistat shortened t lag and t half and decreased the area under the gastric emptying curve. Orlistat significantly attenuated the secretion of glucose-dependent insulinotropic polypeptide (GIP) but did not alter the plasma responses of cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), pancreatic polypeptide (PP), and insulin. There was no peptide YY (PYY) response. Area under the curve of gastric emptying was positively correlated with integrated secretion of GIP (r = 0.786) in orlistat and was negatively correlated with integrated plasma response of GLP-1 (r = -0.75) in control experiments, implying that inhibition of fat absorption modifies determinants of gastric emptying of a meal. Orlistat administered similar to its use in obesity treatment accelerates gastric emptying of a solid mixed meal with a moderate energy load and profoundly attenuates release of GIP without appreciably altering plasma responses of CCK, GLP-1, and PP. Since GIP is being implemented in the development of obesity, its role in weight control attained by orlistat awaits further investigation.
- Subjects :
- Blood Glucose
Male
FOOD-INTAKE
cholecyctokinin
Physiology
glucagon like peptide-1
GUT HORMONES
Enteric Nervous System
Eating
Lactones
Glucagon-Like Peptide 1
Insulin
Meal
GLUCAGON-LIKE PEPTIDE-1
Chemistry
Stomach
digestive, oral, and skin physiology
FREE FATTY-ACIDS
Gastroenterology
Glucagon-like peptide-1
medicine.anatomical_structure
Gastrointestinal hormone
hormones, hormone substitutes, and hormone antagonists
medicine.drug
Adult
brain-gut axis
medicine.medical_specialty
DEPENDENT INSULINOTROPIC POLYPEPTIDE
TYPE-2 DIABETES-MELLITUS
Gastric Inhibitory Polypeptide
Young Adult
Physiology (medical)
Internal medicine
medicine
Humans
Peptide YY
Obesity
Radionuclide Imaging
Pancreatic hormone
Orlistat
PANCREATIC-POLYPEPTIDE
Hepatology
Gastric emptying
LIPASE INHIBITION
glucose-dependent insulinotropic polypeptide
pancreatic polypeptide
Endocrinology
Gastric Emptying
RECEPTOR BLOCKADE
Anti-Obesity Agents
GALLBLADDER CONTRACTION
Subjects
Details
- ISSN :
- 15221547 and 01931857
- Volume :
- 296
- Database :
- OpenAIRE
- Journal :
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Accession number :
- edsair.doi.dedup.....90c4d93349718d5ab75bcbe922fba589